SEARCH:   Advanced

Blood, 15 November 2004, Vol. 104, No. 10, pp. 3058-3063. Prepublished online as a Blood First Edition Paper on June 24, 2004; DOI 10.1182/blood-2003-12-4347. This Article Full Text (PDF) All Versions of this Article: 2003-12-4347v1 104/10/3058    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Tse, W. Articles by Radich, J. P Search for Related Content PubMed PubMed Citation Articles by Tse, W. Articles by Radich, J. P Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted December 23, 2003 Accepted June 19, 2004 Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia William Tse*, Soheil Meshinchi, Todd A Alonzo, Derek L Stirewalt, Robert B Gerbing, William G Woods, Frederick R Appelbaum, and Jerald P Radich Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA; Children's Oncology Group, Arcadia, CA, USA Department of Biostatistics, University of Southern California, Keck School of Medicine, Los Angeles, CA, USA; Children's Oncology Group, Arcadia, CA, USA Children's Oncology Group, Arcadia, CA, USA Department of Pediatric Hematology/Oncology, Emory University School of Medicine, Atlanta, GA, USA; Children's Oncology Group, Arcadia, CA, USA * Corresponding author; email: willtse{at}fhcrc.org. The AF1q gene, an MLL fusion partner, is highly expressed in hematopoietic progenitor cells but has low expression in differentiated cells. We determined the expression of the AF1q gene by RT-PCR in 64 pediatric AML patients treated on Children's Cancer Group clinical trial CCG-2891 and correlated its expression level to clinical characteristics and outcome. AF1q expression in patients varied from 0-154 fold compared to normal marrow, and increasing expression level was associated with worsening survival with a hazard ratio of 1.02 per fold increase in AF1q expression (p=0.032). We divided patients into tertile groups based on AF1q expression level. Patients with high AF1q expression (top tertile) had a higher predominance of FAB M1 compared to patients with lower two tertiles of AF1q expression (43% vs. 9%, p=0.003). High AF1q expression was associated with poor survival in univariate and multivariate models. Overall survival at 8 years for patients with the high AF1q expression was 19% vs. 50% in patients with low AF1q expression, (p=0.01). AF1q expression may correlate with clinical outcome in pediatric AML, though it is not clear if AF1q is simply a marker of a more primitive phenotype, or contributes directly to leukemogenesis. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: B. J. Lange T(11q23): brand necessary Blood, September 17, 2009; 114(12): 2365 - 2366. [Full Text] [PDF] B. V. Balgobind, S. C. Raimondi, J. Harbott, M. Zimmermann, T. A. Alonzo, A. Auvrignon, H. B. Beverloo, M. Chang, U. Creutzig, M. N. Dworzak, et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study Blood, September 17, 2009; 114(12): 2489 - 2496. [Abstract] [Full Text] [PDF] N. N. Co, W. P. Tsang, T. W.L. Wong, H. H. Cheung, T. Y. Tsang, S. K. Kong, and T. T. Kwok Oncogene AF1q enhances doxorubicin-induced apoptosis through BAD-mediated mitochondrial apoptotic pathway Mol. Cancer Ther., October 1, 2008; 7(10): 3160 - 3168. [Abstract] [Full Text] [PDF] S. Meshinchi and R. J. Arceci Prognostic Factors and Risk-Based Therapy in Pediatric Acute Myeloid Leukemia Oncologist, March 1, 2007; 12(3): 341 - 355. [Abstract] [Full Text] [PDF] E. Giovannetti, M. Del Tacca, V. Mey, N. Funel, S. Nannizzi, S. Ricci, C. Orlandini, U. Boggi, D. Campani, M. Del Chiaro, et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res., April 1, 2006; 66(7): 3928 - 3935. [Abstract] [Full Text] [PDF] C. Jacques, O. Baris, D. Prunier-Mirebeau, F. Savagner, P. Rodien, V. Rohmer, B. Franc, S. Guyetant, Y. Malthiery, and P. Reynier Two-Step Differential Expression Analysis Reveals a New Set of Genes Involved in Thyroid Oncocytic Tumors J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2314 - 2320. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020